Pages,Columns,Lines where

d to a collection of information unless it contains a valid CMB control number.

	Application Number		10527406	
	Filing Date		2005-03-11	
INFORMATION DISCLOSURE	First Named Inventor	Wayne Conrad		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1723	
	Examiner Name	CECIL, Terry K.		
	Attorney Docket Numb	er	12800-30/PMdC	

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	of cited Document		Releva		Lines wher ges or Rele	
	1	4906381		1990-03	-06	Donald D. Barbaro					
	2	6120686		2000-09	-19	Roland Bitz					
	3	6398954		2002-06	-04	Yiu Chau Chau	u .				
If you wish to add additional U.S. Patent citation information please click the Add button. Add											
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	ber Code Date Name of Patentee or Applicant Rel		Releva		Lines when ges or Rele				
	1										
If you wis	h to a	dd additional U.S. Publi:	shed Ap	plication	citation	n information p	olease click the Ad	d button.	Add		
				FOREIG	N PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	here Rel	or Relevan	Ts
	1	0381032	EP			1990-08-08	Antonio Carriero				
								_			-

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10527408			
Filing Date		2005-03-11			
First Named Inventor	Wayn	e Conrad			
Art Unit		1723			
Examiner Name CECI		, Terry K.			
Attorney Docket Number		12800-30/PMdC			

	2	1231384	EP		2002-08-14	Vogt Matthias				
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add butto	n Add			
			NON-PATER	NT LITE	RATURE DO	CUMENTS	Remove			
Examiner linitials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country volters publisher.							Ţŝ			
	1									
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE										
Examiner Signature Date Considered										
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

See Kind Codes of USPTO Petent Documents at invest, ISPTO, DDL/or KMPEP 601.04. 2 Enter office that issued the document, by the involved code (WIPO) Standard S13.3 - For Lapraence parter fourments, the articulation of the parent of the register or the present or the serial review of the patient document. A found of coursent by the spropriate symbols as indicated on the document under WIPO Standard S11.6 if possible, "Applicant is to place a check mark here if English tarquages transitions in statistics."

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10527408		
Filing Date		2005-03-11		
First Named Inventor Wayn		e Conrad		
Art Unit		1723		
Examiner Name CECII		L, Terry K.		
Attorney Docket Numb	er	12800-30/PMdC		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 :	and 1.98 to make th	e appropriate selection(s):
---------------	------------	---------------------	-----------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Philip C. Mendes da Costa/	Date (YYYY-MM-DD)	2007-02-08
Name/Print	Philip C. Mendes da Costa	Registration Number	33106

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.